ClinicalTrials.gg

Program

xanomeline

Also written as “KarXT”, “Xanomeline and Trospium Chloride Capsules” and “KarX-EC”.

Its studies are mostly in Schizophrenia · Alzheimer Disease · Mania · Autism Spectrum Disorder · Nausea, led by Bristol-Myers Squibb.

Furthest: phase 4, since Oct 13, 202538 company-led studies, 25 open or runningNext primary completion: Nov 24, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibb3825 open or runningphase 4since Oct 13, 2025Oct 3, 2018Nov 24, 2026phase 3 · NCT06585787

Also a collaborator on its studies: Zai Lab.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 16 studies since Oct 3, 2018.

  1. Mar 17, 2025Phase 3 study in SchizophreniaNCT06882785 · 250 planned · Japan
  2. Apr 14, 20255 phase 3 studiesNCT06929273, NCT06937229, NCT06951711 and 2 more
  3. May 9, 20252 phase 3 studies in Alzheimer DiseaseNCT06976216, NCT06976203
  4. Jun 2, 20252 phase 3 studies in Alzheimer DiseaseNCT07011745, NCT07011732
  5. Jun 23, 2025Phase 1 study in Healthy VolunteersNCT07063342 · 236 planned · United Kingdom
  6. Jul 2, 2025Phase 1 study in SchizophreniaNCT07061288 · 131 planned · United States
  7. Aug 21, 2025Phase 3 study in ManiaNCT07140913 · 424 planned · United States, Argentina, Bulgaria and more
  8. Sep 24, 2025Phase 1 study in Healthy VolunteersNCT07204418 · 56 planned · United States
  9. Oct 13, 2025Phase 4 study in SchizophreniaNCT07221877 · 60 planned · United States
  10. Nov 21, 2025Phase 4 study in Healthy VolunteersNCT07257120 · 10 enrolled · United States
  11. Dec 9, 20253 phase 3 studiesNCT07284745, NCT07285798, NCT07288567
  12. Feb 13, 2026Phase 3 study in SchizophreniaNCT07424404 · 400 planned · United States, Australia, Canada and more
  13. Jun 26, 2026Phase 4 study in NauseaNCT07681076 · 180 planned · United States
  14. Jun 30, 2026Phase 3 study in SchizophreniaNCT07686263 · 472 planned · United States, Argentina, Bulgaria and more

Ahead

  1. Nov 1, 2026Primary completion: phase 3 study in ManiaNCT06951698
  2. Nov 2, 2026Primary completion: phase 3 study in ManiaNCT06951711
  3. Nov 24, 2026Primary completion: phase 3 study in Alzheimer DiseaseNCT06585787
  4. Nov 30, 2026Primary completion: phase 4 study in NauseaNCT07681076

TargetBeta

CHRM1 →CHRM4 →read by rule
“Muscarinic acetylcholine receptor M4 agonist; Muscarinic acetylcholine receptor M1 agonist; Muscarinic acetylcholine receptor M4 agonist; Muscarinic acetylcholine receptor M1 agonist”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
GlycopyrrolateruleNovartisphase 487

Studies

All 38 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07686263Schizophrenia · United States, Argentina, Bulgaria and more3RecruitingMar 3, 2029472
NCT07681076Nausea · United States4RecruitingNov 30, 2026180
NCT07424404Schizophrenia · United States, Australia, Canada and more3RecruitingMar 8, 2030400
NCT07288567Schizophrenia · United States, Colombia, Japan and more3RecruitingDec 18, 2029166
NCT07285798Autism Spectrum Disorder · United States, France, Germany and more3RecruitingAug 6, 2029176
NCT07284745Autism Spectrum Disorder · United States, Australia, Canada and more3RecruitingAug 6, 2029176
NCT07257120Healthy Volunteers · United States4CompletedJun 8, 202610
NCT07221877Schizophrenia · United States4RecruitingDec 30, 202760
NCT07204418Healthy Volunteers · United States1RecruitingDec 3, 202656
NCT07140913Mania · United States, Argentina, Bulgaria and more3RecruitingJun 28, 2027424
NCT07061288Schizophrenia · United States1RecruitingJun 21, 2027131
NCT07063342Healthy Volunteers · United Kingdom1RecruitingMar 29, 2027236
NCT07011745Alzheimer Disease · United States, Argentina, Chile and more3RecruitingNov 3, 2028426
NCT07011732Alzheimer Disease · United States, Argentina, Brazil and more3RecruitingNov 24, 2028426
NCT06976216Alzheimer Disease · United States, Argentina, Australia and more3RecruitingSep 11, 2028586
NCT06976203Alzheimer Disease · United States, Argentina, Australia and more3RecruitingSep 11, 2028586
NCT06947941Alzheimer Disease · United States, Australia, Canada and more3RecruitingFeb 21, 2028325
NCT06951711Mania · United States, China, Croatia and more3RecruitingNov 2, 2026274
NCT06951698Mania · United States, Argentina, Australia and more3RecruitingNov 1, 2026274
NCT06937229Alzheimer Disease · United States, Argentina, Brazil and more3RecruitingJun 22, 2029650
NCT06929273Mania · United States, Argentina, Australia and more3RecruitingJun 13, 2028450
NCT06882785Schizophrenia · Japan3RecruitingSep 23, 2028250
NCT06853171Mental Disorders · United States1CompletedJul 22, 202524
NCT06605950Healthy Volunteers · United States1CompletedMay 31, 202578
NCT06585787Alzheimer Disease · United States, Argentina, Belgium and more3RecruitingNov 24, 2026406
NCT06572449Schizophrenia · United States3CompletedMar 13, 2025173
NCT06126224Psychosis Associated With Alzheimer's Disease · United States, Belgium, Canada and more3RecruitingDec 9, 2026500
NCT05980949Psychosis Associated With Alzheimer's Disease · United States, Argentina, Belgium and more3RecruitingSep 7, 20271,000
NCT05919823Schizophrenia · China3CompletedSep 16, 2024202
NCT05643170Schizophrenia · United States3TerminatedMar 1, 20234
NCT05511363Psychosis Associated With Alzheimer's Disease · United States, Bulgaria, Croatia and more3RecruitingOct 5, 2026410
NCT05304767Schizophrenia · United States, Bulgaria, Japan and more3CompletedMar 25, 2026290
NCT05145413Schizophrenia · United States, Bulgaria, India and more3CompletedMar 19, 2025396
NCT04820309Schizophrenia · United States, Puerto Rico3CompletedMay 24, 2024566
NCT04738123Schizophrenia · United States, Ukraine3CompletedNov 29, 2022256
NCT04659174Schizophrenia · United States, Ukraine3CompletedOct 3, 2023152
NCT04659161Schizophrenia · United States3CompletedMay 24, 2022252
NCT03697252Schizophrenia · United States2CompletedSep 4, 2019182

How it is read

Names in the registry

  • “KarXT”, 21 entries
  • “Xanomeline and Trospium Chloride Capsules”, 9 entries
  • “KarX-EC”, 7 entries
  • “Xanomeline Enteric Capsule”, 3 entries
  • “Xanomeline/trospium chloride”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.